AlphaQuest’s Amicus Therapeutics FOLD Stock Holding History

AlphaQuest’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-142,501	Closed	-$2.03M	–	765
2025 Q4	$2.03M	Buy	142,501 +33,627	+31%	+$330K	0.11%	197
2025 Q3	$858K	Buy	108,874 +27,698	+34%	+$197K	0.06%	496
2025 Q2	$465K	Buy	81,176 +43,765	+117%	+$282K	0.05%	630
2025 Q1	$305K	Buy	37,411 +26,679	+249%	+$247K	0.03%	763
2024 Q4	$101K	Buy	10,732 +9,272	+635%	+$96.4K	0.01%	1084
2024 Q3	$15.6K	Sell	1,460 -598	-29%	-$6.51K	﹤0.01%	1526
2024 Q2	$20.4K	Buy	+2,058	New	+$21.1K	﹤0.01%	1292

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

AlphaQuest's FOLD Position: Q1 2026 in Review

AlphaQuest sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 142,501 shares — an estimated $2.03M sold.

AlphaQuest first reported a position in FOLD in Q2 2024 and held it in 7 quarters. The position peaked at $2.03M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

AlphaQuest reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 142,501 Amicus Therapeutics shares in Q1 2026, an estimated $2.03M.
AlphaQuest first reported a position in Amicus Therapeutics in Q2 2024 and held it in 7 quarters.
AlphaQuest's Amicus Therapeutics position peaked at $2.03M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.